Bristol-Myers Squibb Company (BMY)
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity. BMY's pipeline and recent acquisitions are unlikely to offset revenue declines, with new therapies facing intense competition and limited blockbuster potential. Financial fundamentals are deteriorating, with falling revenue, EBITDA margins, and net income, while high debt and weak free cash flow constrain flexibility.
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
Bristol Myers Squibb trades at seven times earnings, with multiple growth drivers.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Bristol-Myers Squibb Remains Undervalued In 2025
Bristol-Myers Squibb remains my favorite, almost the only Big Pharma stock that hasn't left the accumulation zone. Sales of its "gem" in the cardiovascular franchise, Camzyos, were $296 million in Q3, up 89.7% year-over-year. On the other hand, my concerns about Opdivo Qvantig did not materialize, as its sales reached $67 million, double the Q2 figures.
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
5 High-Yield Blue-Chip Dividend Giants Set to Soar If Rates Fall to 3%
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant passive income stream and have massive total return potential.
